START OF PAGE 1
HOUSE BILL 838

J2, J1 6lr1566
CF SB 562

By: Delegate Cullison
Introduced and read first time: February 4, 2026
Assigned to: Health

A BILL ENTITLED

1 AN ACT concerning

2 State Board of Pharmacy – Prescriber–Pharmacist Agreements

3 FOR the purpose of repealing a requirement that authorized prescribers submit
4 prescriber–pharmacist agreements to the health occupations board that regulates
5 the authorized prescriber; authorizing pharmacists, under certain circumstances, to
6 enter into prescriber–pharmacist agreements that authorize the pharmacist to treat
7 an opioid use disorder using controlled dangerous substances drug therapy;
8 requiring that a protocol that authorizes controlled dangerous substances drug
9 therapy require a pharmacist to request certain data from the Prescription Drug
10 Monitoring Program before initiating or modifying a controlled dangerous
11 substances therapy; and generally relating to prescriber–pharmacist agreements.

12 BY repealing and reenacting, with amendments,
13 Article – Health Occupations
14 Section 12–6A–03, 12–6A–04, and 12–6A–06
15 Annotated Code of Maryland
16 (2021 Replacement Volume and 2025 Supplement)

17 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
18 That the Laws of Maryland read as follows:

19 Article – Health Occupations

20 12–6A–03.

21 (a) An authorized prescriber and a licensed pharmacist who wish to enter into
22 therapy management contracts shall have a prescriber–pharmacist agreement.

23 (b) [(1) (i) Except as provided in subparagraph (ii) of this paragraph, an
24 authorized prescriber who has entered into a prescriber–pharmacist agreement shall

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law. *hb0838*
END OF PAGE 1

START OF PAGE 2
2 HOUSE BILL 838

1 submit to the health occupations board that regulates the authorized prescriber a copy of
2 the prescriber–pharmacist agreement and any subsequent modifications made to the
3 prescriber–pharmacist agreement or the protocols specified in the prescriber–pharmacist
4 agreement.

5 (ii) A health occupations board may enter into an agreement with
6 the Board of Pharmacy that requires authorized prescribers regulated by the health
7 occupations board to submit to the Board of Pharmacy documentation that otherwise would
8 be required to be submitted to the health occupations board under subparagraph (i) of this
9 paragraph.

10 (2)] A licensed pharmacist who has entered into a prescriber–pharmacist
11 agreement shall submit to the Board of Pharmacy a copy of the prescriber–pharmacist
12 agreement and any subsequent modifications made to the prescriber–pharmacist
13 agreement or the protocols specified in the prescriber–pharmacist agreement.

14 12–6A–04.

15 (A) [A] SUBJECT TO SUBSECTION (B) OF THIS SECTION, A pharmacist is
16 authorized to enter into a prescriber–pharmacist agreement if the pharmacist:

17 (1) Is a licensed pharmacist;

18 (2) Has a Doctor of Pharmacy Degree or equivalent training as established
19 in regulations adopted under this subtitle;

20 (3) Is approved by the Board to enter into a prescriber–pharmacist
21 agreement with an authorized prescriber in accordance with this subtitle; and

22 (4) Meets the requirements that are established by regulations adopted
23 under this subtitle.

24 (B) A PHARMACIST MAY ENTER INTO A PRESCRIBER–PHARMACIST
25 AGREEMENT THAT AUTHORIZES A PHARMACIST TO TREAT AN OPIOID USE DISORDER
26 USING CONTROLLED DANGEROUS SUBSTANCES DRUG THERAPY IF THE
27 PHARMACIST:

28 (1) INDIVIDUALLY REGISTERS WITH THE FEDERAL DRUG
29 ENFORCEMENT AGENCY;

30 (2) INDIVIDUALLY REGISTERS WITH THE OFFICE OF CONTROLLED
31 SUBSTANCES ADMINISTRATION;

32 (3) COMPLETES ANY APPLICABLE TRAINING REQUIRED BY FEDERAL
33 OR STATE LAWS; AND
END OF PAGE 2

START OF PAGE 3
HOUSE BILL 838 3

1 (4) FOLLOWS A PROTOCOL THAT MEETS THE REQUIREMENTS OF §
2 12–6A–06 OF THIS SUBTITLE.

3 12–6A–06.

4 (a) A protocol under this subtitle:

5 (1) May authorize:

6 (i) For protocols by a licensed physician and licensed pharmacist,
7 the initiation of drug therapy under written, disease–state specific protocols;

8 (ii) The modification, continuation, and discontinuation of drug
9 therapy under written, disease–state specific protocols;

10 (iii) The ordering of laboratory tests; and

11 (iv) Other patient care management measures related to monitoring
12 or improving the outcomes of drug or device therapy; and

13 (2) May not authorize acts that exceed the scope of practice of the parties
14 to the therapy management contract.

15 (b) A protocol shall prohibit the substitution of a chemically dissimilar drug
16 product by the pharmacist for the product prescribed by the authorized prescriber, unless
17 permitted in the therapy management contract.

18 (C) A PROTOCOL THAT AUTHORIZES CONTROLLED DANGEROUS
19 SUBSTANCES DRUG THERAPY SHALL REQUIRE THE PHARMACIST TO REQUEST
20 RELEVANT DATA FROM THE PRESCRIPTION DRUG MONITORING PROGRAM BEFORE
21 INITIATING OR MODIFYING A CONTROLLED DANGEROUS SUBSTANCES DRUG
22 THERAPY.

23 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July
24 1, 2026.
END OF PAGE 3